bevacizumab,durvalumab,atezolizumab,gemcitabine
astrazeneca,roche
[]
#gi23 presented imbrave151 a randomized ph2 trial of gem-cis-atezo +/- bev no major in mpfs. mos data not yet mature but the mos of gem-cis-atezo was actually worse than current options dr. el-khoueiry acknowledged that gem-cis-durva is still the soc 
GI Onc at Hopkins, focusing on #PancreaticCancer, #PrecisionMedicine. Striving to improve patient outcomes.
Originator of #TumorBoardTuesday @TumorBoardTues